Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why BeiGene Is Soaring 13.8% Today

By Todd Campbell - Jan 18, 2018 at 1:39PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's wallet is about to get a bit thicker.

What happened

After pricing an offering of its American depositary shares (ADSs) at $101, BeiGene ( BGNE -1.29% ) is rallying 13.8% at 1:00 p.m. EST.

So what

BeiGene has been a hot stock since last summer when it teamed up with Celgene Corp. ( CELG )

Chinese coins on top of a red envelope containing Chinese money.


As part of that deal, BeiGene received rights to market Celgene's drugs in China for the next 10 years and Celgene got ex-Asia rights to BeiGene's PD-1 drug, tislelizumab, formerly BGB-A317. Celgene also acquired a 5.9% equity stake in BeiGene.

Today, BeiGene announced its priced a follow-on public offering of 7,425,750 ADSs, each representing 13 of its ordinary shares, at $101.00 per ADS. At that price, BeiGene expects to collect gross proceeds before fees of $750 million. Investors can also take advantage of an overallotment option representing an additional 495,050 ADSs.

Now what

It's busy days for BeiGene. The company has a slate of trials ongoing and planned for its PD-1 inhibitor, BTK inhibitor, and PARP inhibitor, including various combination studies. Altogether, BeiGene's working on 40 clinical trials involving over 2,000 patients, including nine planned studies of tislelizumab.

The flurry of activity means BeiGene's expenses are climbing, so news of the offering shouldn't be surprising. The money it raises via the ADS sale should put it in an excellent position to commercialize Celgene's drugs and launch its own drugs in China, including tislelizumab and its BTK-inhibitor, zanubrutinib, both of which BeiGene hopes to file for approval of this year in China.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BeiGene Stock Quote
$343.20 (-1.29%) $-4.49
Celgene Corporation Stock Quote
Celgene Corporation

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/29/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.